No Clinical, Biochemical Changes Observed After Switch to Adalimumab Biosimilar for IBD hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.
A radioactive tracer developed by Astra Zeneca and the Karolinska Institutet may play a major role for patients with Crohn s disease. That is the belief of Maria Belvisi at AstraZeneca.
Vedolizumab had greater treatment persistence than tofacitinib in a retrospective study of patients with ulcerative colitis (UC) who were previously bio-naive.
Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn's disease, according to a new study.